Release
Details

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:

Tuesday, October 10, 2017
Chardan Gene Therapy Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences & eXtellia
Location: New York, New York
Presentation Time: 2:45 pm EDT

Thursday, October 12, 2017
Jefferies Gene Therapy and Editing Summit
Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and Founder
Location: New York, New York
Presentation Time: 1:40 pm EDT

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia’s website for 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Intellia Contacts:

Media Contact:                                                           
Jennifer Mound Smoter                                             
Senior Vice President, External Affairs                     
& Communications                                                    
+1 857-706-1071                                                       
jenn.smoter@intelliatx.com

Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com

Source: Intellia Therapeutics, Inc.